Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $3.2 million.

  • Inhibrx Biosciences' Share-based Compensation rose 708.26% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 8163.9%. This contributed to the annual value of $58.5 million for FY2024, which is 13552.28% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Share-based Compensation is $3.2 million, which was up 708.26% from $2.8 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Share-based Compensation high stood at $46.2 million for Q2 2024, and its period low was $2.4 million during Q1 2025.
  • In the last 3 years, Inhibrx Biosciences' Share-based Compensation had a median value of $3.2 million in 2025 and averaged $8.9 million.
  • Within the past 5 years, the most significant YoY rise in Inhibrx Biosciences' Share-based Compensation was 708.26% (2025), while the steepest drop was 9400.1% (2025).
  • Inhibrx Biosciences' Share-based Compensation (Quarter) stood at $6.4 million in 2023, then tumbled by 53.6% to $3.0 million in 2024, then increased by 6.47% to $3.2 million in 2025.
  • Its Share-based Compensation was $3.2 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.4 million in Q1 2025.